Drug Profile
HM 15910
Alternative Names: HM15910Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Glucagon-like peptides
- Mechanism of Action Glucagon-like peptide 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Short bowel syndrome
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Short-bowel-syndrome in South Korea
- 25 Apr 2017 Preclinical trials in Short bowel syndrome in South Korea (unspecified route)